Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) reported Q2 EPS of ($0.29), $0.14 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $26.97 million versus the consensus estimate of $28.42 million.
GUIDANCE:
Kiniksa Pharmaceuticals, Ltd. sees FY2022 ARCALYST revenue of $115-130 million.